


Hepatosplenomegaly in a Lean Patient. Apparent Fatty Liver Disease



What's in your differential?

What would you expect if you had a patient exhibiting:

- ▶ **Hepatomegaly without cholestasis**
- ▶ **Abnormal liver enzymes**
 - Elevated transaminases (AST: 51 U/L, ALT: 44 U/L)
 - Elevated kPa without elevated BMI
 - Elevated GGT (26 U/L)
 - Elevated bilirubin levels
 - Elevated alkaline phosphatase
- ▶ **Low HDL-C (15 mg/dL)**

It's not what you think...

Hepatologists and pediatric gastroenterologists can play a critical role in the early diagnosis of ASMD

ASMD, historically known as Niemann-Pick disease types A, A/B, and B, is a progressive and often life-threatening genetic disease.¹

ALT=alanine aminotransferase; AST=aspartate aminotransferase; BMI=body mass index; GGT=gamma-glutamyl transferase; HDL-C=high-density lipoprotein cholesterol; kPa=kilopascal.


HEPATOLOGISTS AND PEDIATRIC GASTROENTEROLOGISTS ARE ON THE FOREFRONT OF DIAGNOSING ASMD

Cryptogenic liver disease? Multisystemic involvement? It could be ASMD

- ▶ **ASMD, caused by a deficiency in the enzyme acid sphingomyelinase (ASM),** is a progressive, multisystemic genetic disease that can lead to shortened life span in both children and adults^{1,2}
- ▶ **ASMD symptoms can impact the lungs, liver, and spleen, as well as the hematologic system. Some types of ASMD can also affect the neurological system^{1,2}**
- ▶ **The 3 subtypes of ASMD, type A, type A/B, and type B, have variable onset, presentation, and impacts on life expectancy. Regardless of type, ASMD can lead to lifelong multisystemic complications and uncertainty for patients²**

Identify signs and symptoms to enable early diagnosis

Percentage of patients who experience hallmark signs and symptoms of ASMD^{1,3*}



*Symptom prevalence data for splenomegaly, hepatomegaly, interstitial lung disease, and thrombocytopenia are only for patients with ASMD type B.

†Symptom prevalence data for gastrointestinal issues are for patients with all ASMD types.


Hepatologists and pediatric gastroenterologists can play a key role in suspecting and diagnosing ASMD: **Early diagnosis is imperative for initiating symptom management and family screening²**

LIVER DISEASE: A LEADING CAUSE OF DEATH IN ASMD⁴

Patients with ASMD can experience significant morbidity and early mortality⁵

By age 35, ASMD type B patients have **~30% reduced survival probability** compared to the general US population[†]

Primary causes of death in patients with ASMD types A/B and B⁴




Cassiman D, et al. *Mol Genet Metab.* 2016;118(3):206-213.

Liver disease was also a common comorbidity in patients whose primary causes of death were listed as respiratory, cardiac, or multiorgan failure⁴

Based on a retrospective global study of 85 patients with ASMD that evaluated the causes of death and disease-related morbidity among patients with ASMD types A/B (n=27) and B (n=58). Data for 85 patients who died (n=78) or received liver transplant (n=7) were collected by treating physicians (n=27) or abstracted from previously published case studies (n=58).⁴

Know the hepatic signs

Splenomegaly, hepatomegaly, and liver fibrosis are hallmark signs of ASMD[§]



ASMD patients may be at risk of cirrhosis, portal hypertension, and variceal bleeding^{1,2,4}

Patients may also present with additional hepatic signs and symptoms, including^{1,2}:

- ▶ **Abnormal liver chemistry tests**
- ▶ **Cryptogenic cirrhosis**
- ▶ Dyslipidemia
 - Elevated total cholesterol
 - Elevated LDL-C
 - Low HDL-C
 - Elevated VLDL-C
 - Elevated triglycerides

[†]Data extrapolated from a Kaplan-Meier curve generated in an 11-year natural history study that evaluated morbidity and mortality in 59 patients with ASMD type B. At entry, 30 patients were in the pediatric age group (<18 years of age) and 29 patients were adults (≥18 years of age). There were 9 deaths during the follow-up period. Reduction in survival probability is absolute, not relative. US general population as of 2017.⁵

LDL-C=low-density lipoprotein cholesterol; MRI=magnetic resonance imaging; VLDL-C=very low-density lipoprotein cholesterol.

ASMD SIGNS AND SYMPTOMS OFTEN OVERLAP WITH OTHER LIVER DISEASES


ASMD patients can experience diagnostic delays of ~5 YEARS⁷

Phenotypic overlap with other hepatic conditions often leads to diagnostic delays²

Hepatic manifestations of ASMD may mimic²:

- ▶ Nonalcoholic fatty liver disease (NAFLD)
- ▶ Autoimmune hepatic disease
- ▶ Chronic hepatitis B
- ▶ Cryptogenic cirrhosis
- ▶ Lysosomal acid lipase deficiency

Consider ASMD in patients presenting with liver abnormalities including:



The diagram features two human silhouettes, one for a child and one for an adult, positioned to the left of their respective text boxes. The child silhouette is on the left, and the adult silhouette is on the right. The text boxes are light blue with a dark blue border at the bottom.

In pediatric patients:

- ▶ Both dyslipidemia and abnormal LFTs⁷
- ▶ Hepatosplenomegaly without cholestasis or obesity²
- ▶ Apparent fatty liver disease and elevated liver enzymes without obesity²

In adult patients:

- ▶ Cryptogenic liver disease with splenomegaly²
- ▶ Fatty liver disease (NASH, NAFLD) with abnormal lipid profiles²

UNEXPLAINED HEPATOSPLENOMEGALY? IT COULD BE ASMD. TEST TO KNOW

Missed diagnoses are common²

ASMD also shares the signs of other, more commonly seen multisystemic conditions

Because of the multisystemic nature of ASMD, it is also confused with other conditions including^{1,2,8-10}:

- ▶ Acute lymphoblastic leukemia
- ▶ Non-Hodgkin lymphoma
- ▶ Congestive heart failure
- ▶ Cystic fibrosis
- ▶ Interstitial lung disease
- ▶ Other storage disorders

Know the signs and symptoms

Gaucher disease—another rare lysosomal storage disorder—shares significant phenotypic overlap with ASMD. Similar to ASMD, Gaucher disease is characterized by multisystemic and progressive symptoms that vary in onset and presentation.¹¹⁰


Among patients suspected of having Gaucher disease, an ASMD diagnosis is not uncommon¹¹

Early detection is the first step to prompt diagnosis and symptom management²

Include ASMD and Gaucher disease in your differential diagnosis and parallel test²

IN ASMD, SPLENOMEGALY AND HEPATOMEGALY OFTEN PRESENT FIRST

A diagnostic approach for ASMD based on expert guidelines²



Guidelines recommend **parallel testing** for ASMD and Gaucher disease due to overlap of clinical manifestations^{2,10*}

ASMD


ASM biochemical enzyme assay

Gaucher disease

β-glucosidase biochemical enzyme assay

TAKE THE STEP TOWARD AN ACCURATE DIAGNOSIS

Suspect ASMD? Diagnostic testing is simple²



[†]Limitations of DBS testing include the potential effects of anemia and recent transfusions on results. Skin fibroblasts or *SMPD1* gene sequencing can be used in equivocal cases.



APRIL
Living with ASMD type B



Additional diagnostic confirmation can be achieved using molecular genetic testing²

An accurate ASMD diagnosis can enable early symptom management efforts from a multidisciplinary care team before disease progression becomes severe²

Cryptogenic liver disease?
Abnormal liver enzymes?
Hepatosplenomegaly?

IT COULD BE ASMD

ASMD, historically known as Niemann-Pick disease types A, A/B, and B, is a multisystemic disease marked by liver dysfunction that can lead to significant morbidity and early mortality¹

Hepatologists and pediatric gastroenterologists can make a difference

- ▶ Liver disease is a leading cause of mortality in ASMD⁴
- ▶ Know the hallmark signs and symptoms of ASMD that affect both children and adults¹
 - Hepatomegaly
 - Interstitial lung disease
 - Splenomegaly
 - Thrombocytopenia

Include ASMD and Gaucher disease in your differential to enable early diagnosis and symptom management

- ▶ Guidelines recommend **parallel testing** for ASMD and Gaucher disease due to overlap of clinical manifestations^{2,10}



SUSPECT ASMD? TEST TO KNOW

Diagnostic testing is simple—confirm a diagnosis of ASMD with an ASM biochemical enzyme assay²

Find more information on ASMD and testing at **ASMDfacts.com/HCP**

References: 1. McGovern MM, Avetisyan R, Sanson B-J, Lidove O. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). *Orphanet J Rare Dis.* 2017;12(1):41. 2. McGovern MM, Dionisi-Vici C, Giugliani R, et al. Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency. *Genet Med.* 2017;19(9):967-974. 3. Cox GF, Clarke LA, Giugliani R, McGovern MM. Burden of illness in acid sphingomyelinase deficiency: a retrospective chart review of 100 patients. *JIMD Rep.* 2018;41:119-129. 4. Cassiman D, Packman S, Bembi B, et al. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): literature review and report of new cases. *Mol Genet Metab.* 2016;118:206-213. 5. Data on file. Sanofi Genzyme. 6. Thurberg BL, Wasserstein MP, Schiano T, et al. Liver and skin histopathology in adults with acid sphingomyelinase deficiency (Niemann-Pick disease type B). *Am J Surg Pathol.* 2012;36(8):1234-1246. 7. McGovern MM, Wasserstein MP, Giugliani R, et al. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. *Pediatrics.* 2008;122:e341-e349. 8. Leukemia & Lymphoma Society. Acute lymphoblastic leukemia signs and symptoms. Accessed December 16, 2021. <https://www.lls.org/leukemia/acute-lymphoblastic-leukemia/signs-and-symptoms> 9. Leukemia & Lymphoma Society. Non-Hodgkin lymphoma signs and symptoms. Accessed December 16, 2021. <https://www.lls.org/lymphoma/non-hodgkin-lymphoma/signs-and-symptoms> 10. Mistry PK, Cappellini MD, Lukina E, et al. A reappraisal of Gaucher disease—diagnosis and management algorithms. *Am J Hematol.* 2011;86(1):110-115. 11. Oliva P, Mechtler TP, Schwarz M, et al. Differential diagnosis of Niemann-Pick A/B disease (ASMD) in cases of suspected Gaucher disease. Poster presented at: 17th Annual WORLDSymposium; February 8-12 2021; San Diego, CA; Poster 305.